Abstract 470P
Background
Glioblastoma multiforme (GBM) is the most common malignant brain tumor. MRPs are involved in mitochondrial translation, with previously revealed role in cancer. Here we aimed to understand their role in GBM.
Methods
Differentially expressed genes (DEGs) were identified through the ‘DESeq2' on R and GEO2R. Survival analysis with optimal expression cutoff for Overall Survival (OS) and median cutoffs for Disease-Free Survival (DFS) based on TCGA-GBM was done using the ‘survival' and 'survminer' R packages, and GEPIA2 online tool. Gene Set Enrichment Analysis (GSEA) was performed using Enrichr tool. miRNA-mRNA networks were constructed using MultiMiR and CytoScape. Immune and methylation analyses were conducted using TIMER2.0 (XCELL) and cBioPortal.
Results
OS estimates indicated worse survival in patients with higher expression of selected MRPs (Table). Further analysis indicated that elevated expression of MRPS33 and MRPL23 is correlated with decreased DFS, with Hazard Ratios (HRs) of 1.80 (p = 0.0012) and 1.70 (p = 0.0039), respectively. GSEA on upregulated genes in high MRPS33-expressers revealed relations to PDGF, NCAM1 interactions, EMT, and integrins in angiognesis. miRNA-mRNA network has identified hub miRNAs, like hsa-miR-1-3p, to have validated interactions with MRPs of interest. Expression of MRPL41, MRPL35, and MRPS33, had negative correlations with HM27/HM450 methylation (Spearman's rho = -0.41, -0.20, and -0.19, respectively; p < 0.05). Finally, there was a positive correlation between MRPS33 expression and Macrophage M2 infiltration in GBM (rho = 0.393, p < 0.05). Table: 470P
Selected MRPs gene expression and GBM patient survival, HR > 1 suggests a harmful effect of the gene on survival
Gene | HR | P Value | 95% CI | DE |
MRPL41 | 1.732784 | 0.0047 | (1.35, 2.11) | D |
MRPL32 | 1.946699 | 0.0010 | (1.55, 2.34) | U |
MRPL17 | 1.787801 | 0.0070 | (1.37, 2.21) | U |
MRPL23 | 1.689083 | 0.0103 | (1.29, 2.09) | U |
MRPS33 | 1.58498 | 0.0226 | (1.19, 1.98) | U |
DE: Differential expression (GBM relative to normal) across GSE4290, GSE68848, and TCGA-GBM (overlap); U: Upregulated; D: Downregulated.
Conclusions
Our study identified a complex multi-omic framework through which MRPs are regulated and play their prognostic and tumorigenic roles in GBM.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
547P - Artificial Intelligence-powered analysis of the tumor immune microenvironment in primary and metastatic colorectal cancer
Presenter: Elio Adib
Session: Poster session 16
548P - Simplified immune score based on CD8+ T-cells at the invasive margin provides comparable prognostic value to immune scores in non-metastatic colorectal cancer
Presenter: Durgesh Wankhede
Session: Poster session 16
549P - Combined morphometric immune signatures define the prognosis of patients with resectable colorectal liver metastases
Presenter: Markus Moehler
Session: Poster session 16
550P - The impact of mismatch repair status on accuracy of clinical staging in upfront resected stage II/III rectal cancer in the Netherlands
Presenter: Renee Lunenberg
Session: Poster session 16
551P - Efficacy prediction of chemoradiotherapy plus anti-PD-1/PD-L1 treatment by magnetic resonance imaging in MSS locally advanced rectal cancer
Presenter: Wentao Tang
Session: Poster session 16
552P - Baseline imaging biomarkers to predict outcomes in locally advanced colon cancer (LACC): Data from the FOxTROT international randomised-controlled trial
Presenter: James Platt
Session: Poster session 16
553P - Association of ctDNA-based MRD detection and MRD clearance with short-term overall survival in patients with resectable colorectal cancer: Updated analysis of CIRCULATE-Japan GALAXY
Presenter: JUN NAGATA
Session: Poster session 16
555P - Association between copy number aberration and ctDNA MRD in colorectal cancer: CIRCULATE-Japan GALAXY
Presenter: TOMOYA HARIMA
Session: Poster session 16